Aaron Leong is interested in the application of complex trait genetics to precision medicine and public health. His research focuses on genetic determinants of hemoglobin A1c, a biomarker used to predict, diagnosis and monitor patients with diabetes. He is involved in genetic discovery efforts led by the Meta-Analysis of Glycemic and Insulin-related Traits Consortium (MAGIC) and the Trans-Omics for Precision Medicine (TOPMed) Program. He hopes to use multi-ethnic cohorts and biorepositories-linked with electronic health data, e.g., Partner Biobank, to perform Mendelian Randomization studies that test causal associations between diabetes drug targets with hemoglobin A1c, drug response and adverse events, diabetes progression, complications and comorbidities, and determine whether genetics of diabetes and related traits can be used to predict health outcomes and improve healthcare utilization.
Aaron enjoys watching TV, Neflix, and movies across multiple genres, traveling, meeting old friends, singing karaoke (when alone), stargazing, palm reading and running.